Bezuclastinib

Name: Bezuclastinib in Nonadvanced systemic mastocytosis: Pharmacokinetics
Published: 2026-09-14T15:39:06-04:00

Nonadvanced systemic mastocytosis

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the second half of 2026
Last updated: September 17, 2026

Section

Product information and disease description Product description Product information Pharmacology

Pharmacokinetics

2 evidence topics · 1 source

Pharmacokinetics: healthy-adult, single-dose formulation study

“Bezuclastinib was slowly absorbed after oral administration, reaching median time to maximum concentration 12 to 16 hours post dose.” (opens the source at this quote in a new tab)

Elimination half-life: healthy-adult, single-dose formulation study

“48.6 to 71.4 hours.” (opens the source at this quote in a new tab)